Last reviewed · How we verify
PRIVIGEN (CSL Behring)
PRIVIGEN is an intravenous immunoglobulin (IVIg) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and replace deficient immunoglobulins.
PRIVIGEN is an intravenous immunoglobulin (IVIg) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and replace deficient immunoglobulins. Used for Primary immunodeficiency syndromes, Secondary immunodeficiencies (e.g., chronic lymphocytic leukemia, HIV infection), Idiopathic thrombocytopenic purpura (ITP).
At a glance
| Generic name | PRIVIGEN (CSL Behring) |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Intravenous immunoglobulin (IVIg) |
| Target | Fc receptors, complement system, pathogenic antigens and antibodies |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
PRIVIGEN contains polyvalent immunoglobulin G (IgG) derived from pooled human plasma, which provides immediate passive immunity and helps regulate aberrant immune responses. It works through multiple mechanisms including antibody replacement in immunodeficiency states, immune modulation via Fc receptor engagement, and neutralization of pathogenic autoantibodies and cytokines in autoimmune and inflammatory conditions.
Approved indications
- Primary immunodeficiency syndromes
- Secondary immunodeficiency in hematologic malignancies
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Multifocal motor neuropathy (MMN)
- Immune thrombocytopenia (ITP)
- Post-transfusion purpura
- Autoimmune hemolytic anemia
Common side effects
- Headache
- Fever
- Chills
- Fatigue
- Myalgia
- Nausea
- Thromboembolism
- Aseptic meningitis
- Acute kidney injury
Key clinical trials
- Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children (PHASE4)
- Effect of Privigen Against Graft Loss (PHASE3)
- Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRIVIGEN (CSL Behring) CI brief — competitive landscape report
- PRIVIGEN (CSL Behring) updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI